Although it is recognised that CNO is part of the psoriatic arthritis/spondyloarthropathy spectrum, there are currently no licensed or approved therapies for this condition.92 Therefore, one model would be a single agent industry-led trial, performed in a so called ‘basket trial’ design where several indications are included in the trial for example, IL-17 blocker in extended oligo articular, polyarticular JIA, JPsA, ERA and CNO. The gene discussed is IL17A; the disease is juvenile idiopathic arthritis.